No Detail Found!

Novel targets and entities inducing cellular apoptosis and anti- angiogenic activity in retinoblastoma management

Author(s)
Zirwa Abdul Rauf College of Life Science, Anhui Agricultural University, Hefei, China
Muhammad Hamza Zahid College of Life Science, Anhui Agricultural University, Hefei, China
Guofeng College of Life Science, Anhui Agricultural University, Hefei, China
Zaigui Wang College of Life Science, Anhui Agricultural University, Hefei, China
Abstract
Retinoblastoma (Rb) represents a primary pediatric cancer, which if left untreated can invade to the nervous system that primarily occurs due to loss of the RB1 gene. Several clinically available therapies are used for the management of risk factors associated with Rb including chemotherapy, brachytherapy, external beam radiotherapy etc. However each treatment has its own side eefcts. To meet with the best approaches in order to minimize these side eefcts novel targeted therapies have been developed that inhibits tumor in an angiogenicdependent manner. This review provides the insights about some targets and the pharmaceuticals with their possible mechanism of action that targets angiogenesis and induces apoptosis. The targets include activation of p53 via controlling mouse double minute homolog 2, survivin, and thrombospondin-1. Enties described in this review include 5-aminoimidazole-4-carboxamide ribonucleotide, niclosamide, bevacizumab, aflibercept, genistein and quercetin and their potential in treating Rb. Also, the signaling pathways that are aefcted in response to these drugs like activated protein kinase pathway, Wnt/ß-catenin pathway, vascular endothelial growth factor and its receptors has also been discussed.
Publication Details
Page(s) 76-85
Published Journal: Biomedica, Volume: 37, Issue: 2, Year: 2021

Request the full text from PASTIC

Keywords
Retinoblastoma, Angiogenesis inhibitors, signaling pathways, p53 activation
References
Dimaras H,Corson TW .2019 .Retinoblastoma, the visible CNS tumor: a review. J Neurosci Res, 97(1) : 29-44.
Webb AH,Gao BT,Goldsmith ZK,Irvine AS,Saleh N,Lee RP .2017 .Inhibition of MMP and MMP-9 decreases cellular migration, and angiogenesis in in vitro models of retinoblastoma. BMC Cancer, 17(1) : 434.
Youssef NS,Said AM .2014 .Immunohistochemical expression of CD117 and vascular endothelial growth factor in retinoblastoma: possible targets of new therapies. Int J Clin Exp Pathol, 7(9) : 5725-37.
Kivelä T. .2008 .The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol, 93(9) : 1129-31.
Rushlow DE,Mol BM,Kennett JY,Yee S,Pajovic S,Thériault BL .2013 .Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. Lancet Oncol, 13(4) : 70045-7.
Bejjani A,Choi MR,Cassidy L,Collins DW,O'Brien JM,Murray T .2012 .RB116: an RB1+ retinoblastoma cell line expressing primitive markers. Mol Vis, 8(1) : 2805-13.
Athavale V,Khetan V .2018 .Kundson to embryo selection: a story of the genetics of retinoblastoma. Taiwan J Opthalmol, 37(1) : 18-20.
Thériault BL,Dimaras H,Gallie BL,Corson TW .2014 .The genomic landscape of retinoblastoma: a review. Clin Experiment Ophthalmol, 42(1) : 33-52.
Li J,Zhang Y,Wang X,Zhao R .2017 .MicroRNA-497 overexpression decreases proliferation, migration and invasion of human retinoblastoma cells via targeting vascular endothelial growth factor A. Oncol Lett, 13(6) : 5021-7.
Li Z,Li Q,Wang G,Huang Y,Mao X,Zhang Y .2017 .Inhibition of Wnt/β-catenin by anthelmintic drug niclosamide effectively targets growth, survival, and angiogenesis of retinoblastoma. Am J Transl Res, 9(8) : 3776-86.
Stenfelt S,Blixt MKE,All-Ericsson C,Hallböök F,Boije H. .2017 .Heterogeneity in retinoblastoma: a tale of molecules and models. Clin Transl Med, 6(1) : 42.
Gao J,Zeng J,Guo B,He W,Chen J,Lu F .2016 .Clinical presentation and treatment outcome of retinoblastoma in children of South Western China. Medicine (Baltimore), 95(42) : .
Reddy SC,Anusya S. .2010 .Clinical presentation of retinoblastoma in Malaysia: a review of 64 patients. Int J Ophthalmol, 3(1) : 64-8.
Abramson DH,Shields CL,Munier FL,Chantada GL .2015 .Treatment of retinoblastoma in 2015: agreement and disagreement. JAMA Ophthalmo, 133(11) : 1341-7.
Dunkel IJ,Shi W,Salvaggio K,Marr BP,Brodie SE,Gobin YP .2014 .Risk factors for severe neutropenia following intraarterial chemotherapy for intra-ocular retinoblastoma. PLoS One, 9(10) : .
Creighton CJ,Fountain MD,Yu Z,Nagaraja AK,Zhu H,Khan M .2010 .Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. Cancer Res, 09(5) : 0008-5472.
Du M,Wang J,Chen H,Wang S,Chen L,Xu Y .2018 .MicroRNA 200a suppresses migration and invasion and enhances the radiosensitivity of NSCLC cells by inhibiting the HGF/c Met signaling pathway. Oncology Rep, 41(1) : 1497-508.
Peng C,Li N,Ng YK,Zhang J,Meier F,Theis FJ .2012 .A unilateral negative feedback loop between miR-200 microRNAs and Sox2/E2F3 controls neural progenitor cell-cycle exit and differentiation. J Neurosci, 32(38) : 12-308.
Montoya V,Fan H,Bryar PJ,Weinstein JL,Mets MB,Feng G .2015 .Novel miRNA-31 and miRNA-200a-mediated regulation of retinoblastoma proliferation. PLoS One, 10(9) : .
Li D,Hu C,Li H C .2018 .: survivin as a novel target protein for reducing the proliferation of cancer cells (Review). Biomed Rep, 8(1) : 399-406.
Garg H,Suri P,Gupta JC,Talwar GP,Dubey S. .2016 .Survivin: a unique target for tumor therapy. Cancer Cell Int, 16(1) : 49.
Jaiswal PK,Goel A,Mittal RD .2015 .Survivin: a molecular biomarker in cancer. Indian J Med Res, 141(4) : 159250-5916.
Shehata HH,Ghalia AHA,Elsayed EK,Ziko OO,Mohamed SS .2009 .Detection of survivin protein in aqueous humor and serum of retinoblastoma patients and its clinical significance. Clin Biochem, 10(1) : 362-6.
Gibson VP,Hardy P,Chain JL .2019 .4:AB045. , : .
Ferrario A,Luna M,Rucker N,Wong S,Lederman A,Kim J .2016 .Targeting survivin enhances chemosensitivity in retinoblastoma cells and orthotopic tumors. PLoS One, 11(4) : .
Jeanne A,Schneider C,Martiny L,Dedieu S. .2015 .Original insights on thrombospondin-1-related antireceptor strategies in cancer. Front Pharmacol, 6(1) : 252.
Chen P,Yu N,Zhang Z,Zhang P,Yang Y,Wu N .2016 .Thrombospondin-1 might be a therapeutic target to suppress RB cells by regulating the DNA double-strand breaks repair. Oncotarget, 7(5) : 6105-20.
Xu XL,Singh HP,Wang L,Qi DL,Poulos BK,Abramson DH .2014 .Rb suppresses human cone-precursor-derived retinoblastoma tumours. Nature, 514(7522) : 385-8.
Laurie NA,Shih CS,Dyer MA .2007 .Targeting MDM2 and MDMX in retinoblastoma. Curr Cancer Drug Targets, 7(7) : 689-95.
Qi DL,Cobrinik D. .2016 .MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation. Oncogene, 36(13) : 1760-9.
Folkman J.,Introduction J. .1990 .. Cancer Metastasis Rev, 9(3) : 171-4.
Garcia JR,Gombos DS,Prospero CM,Ganapathy A,Penland RL,Chevez-Barrios P .2015 .Expression of angiogenic factors in invasive retinoblastoma tumors is associated with increase in tumor cells expressing stem cell marker Sox2. Arch Pathol Lab Med, 139(1) : 1531-8.
Baumann P,Mandl-Weber S,Emmerich B,Straka C,Schmidmaier R .2007 .Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells. Exp Cell Res, 06(16) : 3592-603.
Rehman G,Shehzad A,Khan AL,Hamayun M. .2014 .Role of AMPactivated protein kinase in cancer therapy. Arch Pharm (Weinheim), 347(7) : 457-68.
Shaw RJ,Bardeesy N,Manning BD,Lopez L,Kosmatka M,DePinho RA .2004 .The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell, 06(1) : 91-99.
Theodoropoulou S,Kolovou PE,Morizane Y,Kayama M,Nicolaou F,Miller JW .2010 .Retinoblastoma cells are inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase. FASEB J, 24(8) : 152546-30.
.2011 .also regulated by ADP? Trends Biochem Sci. , 06(9) : 470-7.
Vazquez-Martin A,Oliveras-Ferraros C,Menendez JA .2009 .The active form of the metabolic sensor: AMP-activated protein kinase (AMPK) directly binds the mitotic apparatus and travels from centrosomes to the spindle midzone during mitosis and cytokinesis. Cell Cycle, 8(1) : 2385-98.
Shackelford DB,Shaw RJ .2009 .The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer, 9(8) : 563-75.
Theodoropoulou S,Brodowska K,Kayama M,Morizane Y,Miller JW,Gragoudas ES .2013 .Aminoimidazole carboxamide ribonucleotide (AICAR) inhibits the growth of retinoblastoma in vivo by decreasing angiogenesis and inducing apoptosis. PLoS One, 8(1) : .
Li Y,Li PK,Roberts MJ,Arend R,Samant RS,Buchsbaum DJ RS .2014 .Multi-targeted therapy of cancer by niclosamide: a new application for an old drug. Cancer Lett, 04(1) : 8-14.
Satoh K,Zhang L,Zhang Y,Chelluri R,Boufraqech M,Nilubol N .2016 .Identification of niclosamide as a novel anticancer agent for adrenocortical carcinoma. Clin Cancer Res, 15(14) : 1078-0432.
Pan JX,Ding K,Wang CY .2012 .Niclosamide, an old anti-helminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells. Chin. J. Cancer, 31(4) : 178-84.
Arend RC,Londoño-Joshi AI,Gangrade A,Katre AA,Kurpad C,Li Y .2016 .Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer. Oncotarget, 7(52) : 86803-15.
Polakis P. Drugging .2012 .Wnt signalling in cancer. EMBO J, 31(12) : 2737-46.
Zhan T,Rindtorff N,Boutros M. .2016 .Wnt signaling in cancer. Oncogene, 36(1) : 1461-73.
Zhang Q,Cheng Y,Huang L,Bai Y,Liang J,Li X .2017 .Inhibitory effect of carboplatin in combination with bevacizumab on human retinoblastoma in an in vitro and in vivo model. Oncol Lett, 14(5) : 5326-32.
Lee SY,Kim DK,Cho JH,Koh JY,Yoon YH .2008 .Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma. Arch Ophthalmol, 126(7) : 953-8.
Heo JW,Kim JH,Cho CS,Jun HO,Kim DH,Yu YS .2012 .Inhibitory activity of bevacizumab to differentiation of retinoblastoma cells. PLoS One, 7(3) : .
Missotten GS,Schlingemann RO,Jager MJ RO .2010 .Angiogenesis and vascular endothelial growth factors in intraocular tumors. Dev Ophthalmol, 46(1) : 123-32.
Cheng Y,Zheng S,Pan CT,Yuan M,Chang L,Yao Y .2017 .Analysis of aqueous humor concentrations of cytokines in retinoblastoma. PLoS One, 12(5) : .
Avery RL,Pieramici DJ,Rabena MD,Castellarin AA,Nasir MA,Giust MJ MA .2005 .Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology, 11(1) : 363-72.
Ellis LM .2006 .Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin Oncol, 08(5 Suppl 10) : S1-7.
Kim JH,Kim JH,Kim DH,Cho CS,Jun HO,Yu YS .2009 .Neurotrophin receptors TrkA and TrkB in retinoblastoma are differentially expressed depending on cellular differentiation. Tumour Biol, 30(5-6) : 233-41.
Srinivasan R,Zabuawala T,Huang H,Zhang J,Gulati P,Fernandez S .2009 .Erk1 and Erk2 regulate endothelial cell proliferation and migration during mouse embryonic angiogenesis. PLoS One, 4(12) : .
Chau CH,Figg WD .2012 .Aflibercept in pediatric solid tumors: moving beyond the trap. Clin Cancer Res, 12(18) : 1078-0432.
Ciombor KK .2014 .-a decoy VEGF receptor. Curr Oncol Rep, 16(2) : 368.
Ricci V,Ronzoni M,Fabozzi T.,Aflibercept T. .2015 .a new target therapy in cancer treatment: a review. Crit Rev Oncol Hematol, 07(3) : 569-76.
Kim SH,Kim CW,Jeon SY,Go RE,Hwang KA,Choi KC .2014 .Chemopreventive and chemotherapeutic effects of genistein, a soy isoflavone, upon cancer development and progression in preclinical animal models. Lab Anim Res, 30(4) : 143-50.
Areán C,Orellana ME,Abourbih D,Abreu C,Pifano I,Burnier MN .2009 .Expression of vascular endothelial growth factor in retinoblastoma. Arch Ophthalmol, 128(2) : 223-9.
Kim DY,Choi JA,Koh JY,Yoon YH .2016 .Efficacy and safety of aflibercept in in vitro and in vivo models of retinoblastoma. J Exp Clin Cancer Res, 35(1) : 171.
Ganai AA,Farooqi H .2015 .Bioactivity of genistein: a review of in vitro and in vivo studies. Biomed Pharmacother, 10(1) : 30-8.
Pavese JM,Farmer RL,Bergan RC .2010 .Inhibition of cancer cell invasion and metastasis by genistein. Cancer Metastasis Rev, 29(3) : 465-82.
Banerjee S,Li Y,Wang Z,Sarkar FH. .2008 .Multi-targeted therapy of cancer by genistein. Cancer Lett, 03(2) : 226-42.
Wei D,Yang L,Lv B,Chen L .2017 .Genistein suppresses retinoblastoma cell viability and growth and induces apoptosis by upregulating miR-145 and inhibiting its target ABCE1. Mol Vis, 23(1) : 385-94.
Yang XW,Zhang LJ,Huang XH,Chen LZ,Su Q,Zeng WT .2013 .-145 suppresses cell invasion in hepatocellular carcinoma cells: miR-145 targets ADAM17. Hepatol Res, 4(5) : 551-9.
Slusarz A,Shenouda NS,Sakla MS,Drenkhahn SK,Narula AS,Macdonald RS .2010 .Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer. Cancer Res, 09(8) : 0008-5472.
Pratheeshkumar P,Budhraja A,Son YO,Wang X,Zhang Z,Ding S .2012 .Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR- 2 regulated AKT/mTOR/P70S6K signaling pathways. PLoS One, 7(10) : .
Liu H,Zhou M. .2017 .Antitumor effect of quercetin on Y79 retinoblastoma cells via activation of JNK and p38 MAPK pathways. BMC Complement Altern Med, 17(1) : 531.
Huang YC,Kuo CL,Lu KW,Lin JJ,Yang JL,Wu RS .2016 .18α-Glycyrrhetinic acid induces apoptosis of HL-60 human leukemia cells through caspases- and mitochondriadependent signaling pathways. Molecules, 21(7) : 872.
Song W,Zhao X,Xu J,Zhang H .2017 .Quercetin inhibits angiogenesismediated human retinoblastoma growth by targeting vascular endothelial growth factor receptor. Oncol Lett, 14(3) : 3343-8.
0

Citations

0

Downloads

16

Views